Clinical Trials Logo

Clinical Trial Summary

This is a Phase I/II, open, first-in-human (FIH) study of Transebacillus in Patients with malignant pleural and abdominal effusions. It consists of Phase Ia to determine the Maximum tolerated dose (MTD) or Recommended Phase 2 dose (RP2D) of Transebacillus, and Phase Ib/II to explore and confirm the efficacy, safety and Tolerability.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06178003
Study type Interventional
Source The First Affiliated Hospital of Xinxiang Medical College
Contact Yinghua Ji
Phone 13663030446
Email 54234317@qq.com
Status Recruiting
Phase N/A
Start date February 11, 2024
Completion date January 1, 2025

See also
  Status Clinical Trial Phase
Completed NCT04473768 - Clinical Decision Support in Non-typhoidal Salmonella Bloodstream Infections in Children